Comparison · NCT02500602-sae
Doxazosin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Doxazosin vs Placebo: serious adverse events. Trial comparisons, record NCT02500602-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02500602-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.162 | 0.0953 | 0.262 | wilson | |
| Risk in group 2 | 0.129 | 0.0691 | 0.227 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0336 | -0.0851 | 0.15 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.26 | 0.567 | 2.81 | log | |
| Odds ratio, group 1 over group 2 | 1.31 | 0.516 | 3.34 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Doxazosin than on Placebo | 29.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Doxazosin | Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). doxazosin: active medication | 12 | 74 | EG000 |
| Group 2 | Placebo | Participants randomly assigned to receive Placebo pill placebo: placebo pill | 9 | 70 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AEs collected from baseline (if baseline lasted longer than one appointment) through follow up (12 week treatment phase and 6 week follow up - approximately 20 weeks)
Source ClinicalTrials.gov
Trial
- Title
- CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders
- NCT number
- NCT02500602
- Phases
- PHASE2
- Conditions
- Posttraumatic Stress Disorder, Alcohol Use Disorders
- Interventions
- doxazosin, placebo
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2021-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02500602?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02500602-sae